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Summary This study was conducted among individuals taking ﬁrst-line antiretroviral treat-
ment (ART) for at least 12 months under programme conditions in Maputo, Mozambique in order
to report on the level of detectable viraemia and the proportion and types of drug resistance
mutations among those with detectable viral loads. HIV-1 RNA viral load levels (lower detection
limit <50 copies/ml) were measured, and resistance mutations were sequenced. One hundred
and forty-nine consecutive patients (69% females, median age 36 years) were included after
a mean follow-up time of 23 months. One hundred and seven (72%; 95% CI 64—79) had unde-
tectable viral load, while in 42 (28%, 95% CI 21—36) viral load was detectable (range 50—58 884
copies/ml). From 15 patients with viral load >1000 copies/ml, 12 viruses were sequenced:
eight were C subtypes and four were circulating recombinant forms (CRF08). Eight (5%; 95% CI
2—9) patients with detectable viral load had one or more major resistance mutations. Nucleo-
side reverse transcriptase inhibitor (NRTI) and non-NRTI mutations were observed. There werePlease cite this article in press as: Maldonado F, et al. Virae
receiving antiretroviral treatment in Mozambique. Trans R Soc
no major mutations for resistance to protease inhibitors. In Maputo, the level of detectable
viraemia is reassuringly low. While embarking on ART scale-up, wider surveillance is warranted
to monitor programme quality and limit the development of drug resistance, which remains a
major potential challenge for th
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. Introduction
ozambique, a resource-poor country in sub-Saharan Africa,
aces a serious HIV epidemic with a prevalence of 16% in
dults aged 15—49 years. In 2005, an estimated 140 000
eaths in adults and children were attributed to HIV/AIDS.1
Antiretroviral treatment (ART) can dramatically improve
he survival of people living with HIV/AIDS2 and Mozambique
mbarked on a national ART scale-up plan in 2005.3 Effec-
ive ART achieves persistent viral suppression (the virus stays
elow the detection limit of common assays in blood) and
mmunological recovery. If viral suppression is not achieved
or whatever reason, the chronology of events is that the
iral load increases to detectable levels, leading in a second
tep to a signiﬁcant drop in CD4 count (immunological fail-
re) and the development of new or recurrent opportunistic
nfections (clinical failure).4 A detectable viral load implies
ngoing viral replication, which fosters the development of
rug-resistant mutations and constitutes a major potential
roblem for the future of ART in Africa.4,5
Viral load monitoring, which typically measures HIV-1
NA concentrations in plasma, is the most reliable method
or detecting adherence problems and early treatment fail-
re. In industrialized countries, individuals on ART have
oth viral load and CD4 levels measured regularly as part
f routine follow-up. In Mozambique, as in many other
ow-resource countries, routine viral load monitoring is not
et feasible as this depends on the availability of sophis-
icated laboratory facilities. Patient monitoring thus relies
n clinical assessment and, when available, CD4 monitor-
ng. Consequently, virological failure is considered only in
he event of clinical deterioration and/or decrease of CD4
ount.4 The unavoidable lag period, of up to two years,
etween virological failure and these two events is asso-
iated with the development of drug resistance.
Since 2002, Médecins sans Frontières (MSF) has been sup-
orting the Mozambican Ministry of Health (MoH) to offer
RT under routine programme conditions in Mavalane dis-
rict, Maputo. Within a sample of individuals placed on
rst-line ART for at least one year, we report on the level
f detectable viraemia and the proportion and types of
rug resistance mutations among those with detectable viral
oads.
. Methods
.1. Study setting and population
he study was conducted between June and December 2006
n one of the main public day clinics (Primeiro de Maio) that
ffer ART in Maputo. The study population included con-
ecutive ARV-naive individuals who had completed at least
2 months ﬁrst-line ARV treatment, which in Mozambique
omprises a ﬁxed-dose combination of stavudine (d4T),
amivudine (3TC) and nevirapine (NVP) (Triomune), with
idovudine (AZT) and efavirenz (EFV) in association withPlease cite this article in press as: Maldonado F, et al. Virae
receiving antiretroviral treatment in Mozambique. Trans R Soc
amivudine as alternatives in case of side-effects. All HIV-
elated medication and consultation is provided free of
harge.
All HIV-positive individuals who present at the clinic
ndergo a complete medical assessment for HIV-related
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iseases. ART eligibility is guided by CD4 count and in accor-
ance with WHO guidelines.2 Prior to ART initiation patients
eceive at least four counselling/educational sessions (indi-
idual and group-based), and are encouraged to choose a
treatment buddy’, who will be the cornerstone of adher-
nce and support at home. After initiation, patients are
ndividually followed monthly (clinical check and adherence
ounselling) and invited to join support group activities. All
ounselling/educational activities are provided by trained
ay personnel. Immunological monitoring (CD4 count) is done
n a six monthly basis. Adherence to ART is graded according
o both pill count and punctuality of attendance at sched-
led clinical consultations.
At the time of the study, the HIV clinic had 2139 patients
n highly active antiretroviral therapy and was initiating
RT at a rate of 100 new patients per month. At the end
f 2006, standardized treatment outcomes for the entire
ohort included 81% alive and on ART, 8.5% died, 8.5% lost
o follow up, 0% stopped and 2% transferred out.
.2. Specimens and laboratory procedures
iral loads and genotyping were performed on specimens
ransported to the Retrovirology Laboratory, Luxembourg.
lasma was separated from 5ml of drawn blood and 100l
as placed on two separate points on a ﬁlter paper (What-
an Schleicher & Schuell FTA Mini Cards, Kent, UK) and then
ried to obtain dried plasma spots (DPS). The cards were
acked individually in plastic zip-log sachets with desiccant
acks and stored on site at 4 ◦C until transport. The remain-
ng plasma was stored at −20 ◦C. Local laboratory workers
ound the DPS specimens easy to use, store and transport.
Viral load detection was by quantitative RNA-PCR using
PS; the lower detection limit of the assay was <50
opies/ml. Results obtained from DPS were subjected to a
tandardized correction factor based on average known dif-
erences in viral load levels obtained from plasma (the gold
tandard) and DPS stored at 4 ◦C for a period of 1—10 weeks.
rug resistance genotyping was performed on plasma stored
t −20 ◦C and transported on dry ice. Genotyping was per-
ormed on specimens having a viral load of ≥1000 copies/ml
nd drug-resistant mutations compared with the HXB2 wild
ype strain were listed. For the purpose of this study, viro-
ogical failure was deﬁned as a viral load of ≥50 copies/ml,
hich is considered the gold standard threshold.
.3. Data collection, sample size and statistical
nalysis
structured record form and patient cards were used to
ather information. These were entered into standardized
onitoring software (FUCHIA, Epicentre, Paris, France).
he main outcome measure of this study was the level of
etectable viraemia from 12 months after starting ﬁrst-line
RT (virological failure) and the proportion and types of
rug resistance among those with detectable viraemia. Amia and HIV-1 drug resistance mutations among patients
Trop Med Hyg (2008), doi:10.1016/j.trstmh.2008.07.014
revious MSF study conducted in South Africa6 showed a
irological failure rate of 15% at 12 months. We assumed
similar scenario and aimed to detect up to 21% virological
ailure with 95% conﬁdence and 80% power. This required at
east 136 individuals and was the basis of the sample size.
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Table 1 Characteristics of patients with and without detectable (≥50 copies/ml) viral loads
Viral load < 50 copies/ml Viral load ≥50 copies/ml P-valuea
Total (n = 149) 107 (72) [95% CI 64—79] 42 (28) [95% CI 21—36] —
Gender (n) (%)
Male 34 (32) 13 (31) 0.92
Female 73 (68) 29 (69)
Mean age (years) 36.9 34.9 0.57
Baseline WHO clinical stage (n) (%)
Stage 1 12 (11) 5 (12) 0.86
Stage 2 14 (13) 7 (17) 0.57
Stage 3 58 (54) 21 (50) 0.64
Stage 4 23 (21) 9 (21) 0.99
Baseline body mass index (kg/m2) 21.3 20.6 0.54
Baseline CD4 count (cells/l) (mean) 178 103 0.65
Substitution of at least one ARV drugb (n) (%) 19 (18) 13 (31) 0.07
InterruptedcART for at least one month (n) (%) 1 (0.9) 3 (7) 0.12
Delay in attending scheduled appointmentsd (n) (%) 15 (14) 6 (14) 0.57
Duration on ART ≥24 months (n) (%) 44 (41) 22 (52) 0.21
ARV: antiretroviral; ART: antiretroviral treatment.
a X2 test for categorical variables and the Mann-Whitney U test for continuous variables.
b Antiretroviral drug substitution by alternative drug due to speciﬁc toxicity.
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(1).
d Patients arriving with delay for at least one drug reﬁll in the six
This sample size also exceeded the number of consecutive
specimens recommended by the WHO to monitor HIV drug
resistance prevention in sentinel ART sites.7,8 Differences
between groups were compared using the X2 test for cate-
gorical variables and the Mann-Whitney U test for continuous
variables. The level of signiﬁcance was set at P = 0.05 or less
and 95% CIs were used throughout. Analyses were performed
using SPSS version 10.1 (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Characteristics of the study population
At the time of the study there were 1314 ART-naive patients
attending Primeiro de Maio Health Centre who had com-
pleted at least 12 months of ﬁrst-line ART. From these, a
total of 149 consecutive patients (69% women) on follow-up
visits were included in the study after a mean time of 23
months [interquartile range (IQR) 17—28] on ART.
Median age at the start of ART (baseline) was 36.4 years
(IQR 29—42); 75% were in WHO clinical stage 3 or 4; median
CD4 count was 115 cells/l (IQR 58—204) and 23% had a
body mass index under 18.5 kg/m2. ART regimens included
d4T/3TC/NVP in 132 (89%) patients, AZT/3TC/NVP in 11
(7%) patients and d4T/3TC/EFV in 6 (4%) patients. Median
CD4 count at the time of our study was 381 cells/l (IQR
252—529; median gain compared to baseline 266 cells/l)Please cite this article in press as: Maldonado F, et al. Virae
receiving antiretroviral treatment in Mozambique. Trans R Soc
3.2. Viral loads and drug resistance
Of 149 patients who had their viral load measured using DPS,
107 (72%, 95% CI 64—79) had an undetectable viral load (<50
copies/ml), while 42 (28%, 95% CI 21—36) had a detectable
c
C
o
t
me skin reaction (1), suspected lactic acidosis (1), unknown reason
ths prior to study enrolment.
iral load (range 50—58 884 copies/ml). The latter included
0 (7% 95% CI 3—11) with a viral load of 50—399 copies/ml,
7 (11%, 95% CI 7—18) with a viral load 400—999 copies/ml,
0 (7%, 95% CI 3—11) with 1000—9999 copies/ml and 5 (3%,
5% CI 0.4—5) with ≥10 000 copies/ml. The characteristics of
atients with and without a detectable viral load are shown
n Table 1.
Of 15 (10%) specimens with viral load ≥1000 copies/ml,
hree were not ampliﬁable. Of the twelve sequenced speci-
ens, eight belonged to subtype C and four were circulating
ecombinant forms (CRF08). Eight (5%, 95% CI 2—9) had one
r more major mutations. The major nucleoside reverse
ranscriptase inhibitor mutations (NRTI) mutations were
184V (n = 7), T215F (n = 4) and D67N (n = 1) while non-NRTI
NNRTI) mutations included K103N (n = 3), M230L (n = 1),
101E (n = 1), V1081 (n = 2), Y181C (n = 4), V106M (n = 3),
227L (n = 1) and G190A (n = 1) (Table 2). Five patients were
nfected with viruses exhibiting a thymidine analogue muta-
ion (TAM, D67N, T215F). All sequenced isolates displayed
series of polymorphisms at residue positions that have
een associated with protease resistance in subtype B HIV-1.
hese substitutions are natural polymorphisms in non-B sub-
ypes and thus were not interpreted as resistance-coding
utations.
Clinical criteria for suspicion of virological failure (>50
opies/ml) were satisﬁed in only four (9.5%) patients; three
ad apparent unspeciﬁed skin conditions and/or weight
oss of >10% and one had developed an episode of extra-
ulmonary tuberculosis (EPTB). The WHO immunologicalmia and HIV-1 drug resistance mutations among patients
Trop Med Hyg (2008), doi:10.1016/j.trstmh.2008.07.014
riterion for suspicion of virological failure (≥50% drop in
D4 counts from the on-treatment peak2,9 was satisﬁed in
nly three (9%) patients with a detectable viral load. All
hree had viral load titres ≥10 000 virus copies/ml (two had
utations and one was the EPTB case). Five patients had
Please cite this article in press as: Maldonado F, et al. Virae
receiving antiretroviral treatment in Mozambique. Trans R Soc
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rossed the WHO threshold for virological failure (deﬁned
s ≥10 000 copies/ml), of which four (with the exception
f one case of EPTB) exhibited major resistance muta-
ions.
Six cases with resistance mutations in this study were
witched to appropriate second-line ART regimens, while
wo cases remained on ﬁrst-line therapy because of a viral
oad <10 000 copies/ml. All eight patients received inten-
iﬁed adherence support and close monitoring. Eighteen
onths after the study, four cases on second-line and one
ase on ﬁrst-line therapy still presented undetectable viral
oad, two cases on second line were failing virologically and
ne case on ﬁrst-line therapy had a detectable viral load
ssociated with an episode of PTB. The patient with EPTB
ad an undetectable viral load on completion of EPTB treat-
ent.
. Discussion
mong individuals placed on ﬁrst-line ART regimens under
outine programme conditions in Maputo, the level of
etectable viraemia and drug resistance after a mean
ollow-up time of 23 months was reassuringly low. The fact
hat 72% of patients had an undetectable viral load compares
ell with that reported from both developed countries9
nd other resource-limited settings in Africa.10 Reports from
outh Africa, Cote d’Ivoire and Kenya showed the propor-
ion of patients with undetectable viraemia to be 51% (95%
I 26—75) at 24 months.10 Our ﬁgure also exceeds the 70%
ecommended by WHO for drug resistance prevention at 12
onths on treatment.7
The low level of drug resistance is encouraging in this
etting with restricted access to second-line ART as it shows
hat implementation of ART can be achieved with limited
mergence of resistant strains. Another study from Mozam-
ique similarly showed a limited presence of resistant HIV-1
trains.11 We attribute these acceptable results to a num-
er of factors, including standardized ART regimens and
xed-dose combinations, clear and simple management pro-
ocols, uninterrupted drug procurement and supply, ART
ffered free-of-charge, and a standardized monitoring sys-
em. We are of the opinion that lay counsellors have played
critical role in supporting treatment adherence in our set-
ing as they are likely to have positively inﬂuenced patient
mpowerment,12,13 which in turn is likely to have favourably
nﬂuenced the level of viral suppression. Lay counsellors
re not recognized within Ministry of Health structures
n Mozambique but our ﬁnding of very low resistance is,
n our opinion, an important tribute to their work that
hould be ofﬁcially recognised. Speciﬁc studies are, how-
ver, required to establish the relationship between lay
ounsellors and viral suppression. In the meantime, Mozam-
ique has a tremendous shortage of skilled health workers,
nd trained lay counsellors could be actively involved within
he scale-up efforts.
Sub-Saharan African countries, including Mozambique,mia and HIV-1 drug resistance mutations among patients
Trop Med Hyg (2008), doi:10.1016/j.trstmh.2008.07.014
re rolling out ART to thousands of patients countrywide.
ven in a best-case scenario of a 5% (95% CI 2—9) resis-
ance level, clinics which initiate about 100 patients per
onth could have between two and nine patients of this
ohort developing resistance mutations in the medium term.
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If this is multiplied by the hundreds of ART initiation sites
embarking on ART rollout countrywide, the overall impact on
the transmission and prevalence of drug resistant mutations
cannot be underestimated.
Of the 42 patients with a viral load ≥50 copies/ml only
eight were found with drug resistance mutations. This sug-
gests that in the 81% of patients with a detectable viral
load but no apparent mutations, adherence was inade-
quate for some reason, leading to a real risk that these
patients would develop drug resistance over time. Even if
we assumed that viral loads of under 1000 copies/ml might
be related to ‘‘blips’’ (transient viraemia that returns spon-
taneously to undetectable levels without apparent clinical
consequences,14,15) there were only ﬁve (33%) of 15 patients
with viral load titres ≥1000 copies/ml who had clinical
and/or immunological signs suggesting failure. This implies
that routine clinical examinations, pill-count monitoring,
immunological and other existing forms of adherence moni-
toring would still miss the great majority of patients having
inadequate viral suppression. Even when there is excellent
adherence with pill counting, self-reporting or punctual-
ity to clinic visits (measures most developing countries rely
upon for monitoring adherence), these have been shown to
correlate poorly and tend to overestimate adherence as has
been demonstrated in Blantyre, Malawi.16
In Khayelitsha, South Africa, where routine viral load
testing is performed, patients with detectable viral loads
are offered intensive adherence support and counselling and
the viral load is reassessed four weeks later. The ability of
viral loads to return to an undetectable level correlated
with the timing of detection and the subsequent adher-
ence support intervention provided.17 This emphasizes the
important role of viral load measurement as a sensitive and
useful operational support tool for adherence. The develop-
ment of an easy-to-use, semi-quantitative and inexpensive
rapid test to detect early virological failure is not a lux-
ury and would play an important role in optimizing the
response to both ﬁrst- and second-line therapy in developing
countries.17,18
One patient who developed EPTB and who was on both
anti-TB treatment and ART was found to have a viral load
of >10 000 copies/ml but with no mutations. Although we
do not know the precise reasons for this high viral load,
it is likely that this patient stopped ART completely, since
in the absence of drug pressure, mutations do not occur.
Another possibility might be the presence of active TB,
which increases viral loads, although not usually to such an
extent. In any case, the fact that the viral load subsequently
fell to an undetectable level on completion of TB treatment
is encouraging and suggests that in patients who develop
an active opportunistic infection, particularly TB,19 during
the course of ART, further adherence support and viral load
monitoring would be justiﬁed without rushing to a treatment
switch.
The strengths of this study are that it was conducted
under routine programme conditions and the ﬁndings are
thus likely to reﬂect the operational reality. We also usedPlease cite this article in press as: Maldonado F, et al. Virae
receiving antiretroviral treatment in Mozambique. Trans R Soc
an easy-to-use DPS technique to collect and store specimens
and the fact that the yield was very satisfactory implies that
this tool could facilitate wider surveillance.20—22
In terms of limitations, the sample was not subjected
to drug resistance monitoring prior to ART initiation (base-
E
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5
ine resistance testing) and we thus do not know the level
f primary resistance in the cohort. We primarily aimed to
onitor viral suppression as a measure of HIV drug resistance
revention at a particular site. The mutations and resistance
evels in this study thus only reﬂect a snapshot of the situ-
tion at that site. Similar studies will have to be conducted
t other sentinel sites to give a truly representative view of
he situation in Maputo. We have also reported a series of
ubstitutions in the non-B subtypes but do not know the clin-
cal signiﬁcance of such mutations in the longer term. There
as been discussion on the fact that such mutations might
acilitate the development of virological failure during pro-
ease inhibitor therapy and further research in this domain
ould be justiﬁed. Finally, our conclusions are drawn on a
ample of patients within the overall cohort as it was not
easible to offer viral load testing to the entire cohort, and
he related limitations thus apply.
In Maputo, the level of detectable viraemia and the pro-
ortion of patients with drug resistance to ﬁrst-line ART
s reassuringly low. While countries such as Mozambique
re embarking on ART scale-up, wider surveillance is war-
anted to monitor programme quality (particularly aspects
f adherence and patient education) and limit the devel-
pment of drug resistance and the need for second-line
herapies. These remain major potential challenges for the
uture of ART in Africa.
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